< Back to latest news & events

News

Co-Existence Agreements – The importance of getting them right

June 2020

A co-existence agreement allows businesses to trade using the same (or similar) mark, but with certain agreed restrictions, such as geographical constraints where a mark can be used. For example – one party may be able to sell under the mark in Europe, and another can sell under the mark in the USA. The need for this may arise for example where two parties have unknowingly adopted the same mark at the same time.

The recent case of Merck KGaA v Merck Sharp & Dohme Corp and Ors [2020] EWHC 1273 (Ch) concerned a long running trade mark dispute between Merck KGaA (Merck Global) and Merck Sharp & Dohme Corporation (Merck US) and illustrates the importance of making sure co-existence agreements are fit for purpose.

Background

Merck Global was founded in 1688 in Germany. A US subsidiary was established that subsequently became an independent company. A co-existence agreement was entered into in 1955 and then updated in 1970, which set out the parties use of the mark ‘Merck’. This agreement provided that Merck US were fine to use this mark in the US and Canada, however in other countries they would use ‘Merck Sharp & Dohme’ (the company’s full name).

Infringement

Merck Global claimed that online and offline uses of ‘Merck’ in the UK by Merck US breached the co-existence agreement between the parties. In 2016, the High Court found that Merck US’ use of the mark in the UK constituted a breach of the co-existence agreement. Merck US appealed, and the Court of Appeal found in 2017 that Merck US had breached the agreement. The issues of whether these breaches constituted trade mark infringement were referred back to the High Court.

The judge found that Merck US’ use of the mark on websites, email addresses and social media targeted at the UK could constitute “use in the course of trade” (i.e. – physical goods do not actually have to be available, given the fact that Merck US had used a different mark on products actually sold in the UK) and accordingly use in this way constituted trade mark infringement. An injunction was granted against Merck US to prevent it from infringing the mark in the UK.

How can a business get this right?

Ensuring that a co-existence agreement will adequately deal with every eventuality that may arise in the future is obviously impossible. However, the co-existence agreement in this instance appeared to be very simple and had not been updated since 1970 (and consequently could never deal with issues such as whether use on social media constituted infringement). Parties to such an agreement should therefore think about the following;

  • What effect could rapidly evolving technology have on the use of a mark in future. Could this widen the use of a mark, sometimes inadvertently beyond the scope of what was originally intended?
  • Where do you realistically intend to sell products? Basing an agreement on current markets and ignoring potential markets could cause problems down the line.
  • Include adequate dispute resolution processes (for example a requirement to mediate a dispute) in order to hopefully avoid costly and lengthy litigation.
  • Given this case and the effects of the internet and other technology, it may be worthwhile introducing requirements for the agreement to be reviewed (for example every ten years) to make sure it adequately provides for such advancements or changes to the parties’ businesses
  • Don’t just consider geography – consider all elements of hard copy and electronic use including social media, websites, physical marketing brochures and other advertising materials.

This article was prepared by HGF Senior IP Solicitor Chris Robinson. If you would like further advice on this or any other matter, please contact Chris.  Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Latest updates

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

WIPR Diversity Top 100 2025

HGF’s European Patent Attorney Alexandra Wood has been listed in World IP Review’s (WIPR) Diversity Top 100 2025 World IP Review’s Diversity in IP listings 2025 recognises and celebrates people …

Read article

INTA 2025 Annual Meeting Live

The HGF European team will be attending the INTA Annual Meeting Live, which will take place on 17th-21st May in San Diego, US. The conference will connect some of the …

Read article

HGF wins big at the Managing IP EMEA Awards Ceremony 2025

The Annual Managing IP Awards: EMEA Awards 2025 were announced last night, and HGF are proud to have won 7 awards. The Managing IP Awards are highly recognised and respected …

Read article

Plant Patent Infringement in the US Relies on Evidence of Asexual Reproduction

A recent case in the US District Court for the Northern District of Texas (Dallas Division) once again highlights how important the initial pleadings and evidence in patent infringement cases …

Read article

Exam Success at HGF!

HGF is pleased to announce that several of our attorneys have passed their UK Advanced Patent exams! In no specific order, we would like to say well done and a …

Read article

IP Ingredients: How food companies are using IP to stay ahead of the GLP-1 curve

The impact of GLP-1 on the food and beverage sector GLP-1 agonists, best-known under the brand names Ozempic® and Wegovy®, are medicines used to treat type 2 diabetes and obesity. …

Read article